U.S. Ophthalmic Drugs Market Size, Share & Forecast 2026–2032

ID: MR-11499 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Ophthalmic Drugs Market
  • ✓Market Size 2024: USD 12.4 billion
  • ✓Market Size 2032: USD 18.7 billion
  • ✓CAGR: 5.3%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Part B Margin Compression: Medicare Part B reimburses intravitreal anti-VEGF injections at average sales price plus six percent, so Regeneron's Eylea and Genentech's Vabysmo compete on net price. Biosimilar aflibercept receiving ASP plus eight percent under IRA section 11403 is compressing that margin.
FINDING 02
Dry Eye Brands Hold: Conventional wisdom holds that generic cyclosporine will commoditise U.S. dry eye therapy. Branded Restasis and Xiidra have sustained share through prescriber loyalty and formulary positioning, so generic entry will not reset pricing before 2030.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Biosimilar Supply Early: Buyers and biosimilar investors should secure multi-year aflibercept and bevacizumab supply agreements by 2026, before Part B negotiated pricing reshapes intravitreal margins from 2028. Franchise viability through 2032 depends on that contract visibility.

Ophthalmic Drugs in the United States: Market Overview

The U.S. ophthalmic drugs market was valued at USD 12.4 billion in 2024 and is forecast to reach USD 18.7 billion by 2032. Demand splits across three channels: physician-administered intravitreal biologics billed under Medicare Part B, self-administered topical products dispensed through Part D pharmacies, and hospital-based surgical adjuncts. Private manufacturers have led product innovation, while federal payment rules have set commercial boundaries.

Government has dominated pricing and access rather than development. The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created the generic entry framework behind topical glaucoma products. The Biologics Price Competition and Innovation Act of 2009 created the biosimilar pathway now contesting Eylea. Private biotechs have led gene and cell therapy development, while the National Eye Institute funds foundational retinal research.

Policy-Driven Growth in U.S. Eye Medicines

The Biologics Price Competition and Innovation Act created the abbreviated biosimilar approval pathway that FDA's Center for Drug Evaluation and Research uses for aflibercept and bevacizumab-based products. Section 11403 of the Inflation Reduction Act of 2022 pays qualifying Part B biosimilars average sales price plus eight percent through 2027. Physician practices capture that spread, which lowers effective cost per injection and widens treatment-naive patient eligibility.

The Orphan Drug Act of 1983 grants seven years of market exclusivity, and Internal Revenue Code section 45C credits 25 percent of qualified clinical testing costs for orphan indications. Inherited retinal disease programmes depend on these incentives. The Inflation Reduction Act also caps Medicare Part D out-of-pocket spending at USD 2,000 from 2025, improving adherence to chronic topical glaucoma regimens among seniors.

Regulatory Barriers and Compliance Costs

FDA's Center for Drug Evaluation and Research reviews ophthalmic applications under PDUFA VII, which runs through September 2027 and sets a ten-month standard review after a 60-day filing period. Products must satisfy current good manufacturing practice under 21 CFR Parts 210 and 211. The Drug Supply Chain Security Act requires interoperable electronic product tracing, which every ophthalmic stock keeping unit must now carry.

Compounding creates the sharpest local friction. Repackaged bevacizumab syringes for intravitreal use fall under Section 503B of the Federal Food, Drug, and Cosmetic Act, overseen by FDA and state boards of pharmacy. Outsourcing facilities must meet USP chapter 797 sterility standards, and state-by-state licensing adds months of delay and recurring inspection cost. Manufacturers also submit quarterly ASP data to CMS, a reporting burden small firms struggle to absorb.

Policy-Created Opportunities in American Eye Care

Biosimilar aflibercept represents the first opportunity. Section 11403's ASP-plus-eight-percent add-on, combined with the interchangeability pathway FDA is simplifying, makes intravitreal biosimilars commercially attractive for practices that absorb reimbursement spread. Manufacturers able to secure BPCIA approval by 2027 capture the add-on window, which closes after that year.

Orphan gene therapies for inherited retinal disease form the second opportunity, supported by the Orphan Drug Act's exclusivity and the 25 percent section 45C credit. The Department of Veterans Affairs offers a third route through Federal Supply Schedule contracts administered by its Office of Acquisition, Logistics, and Construction, where bulk ophthalmic purchasing favours manufacturers with national distribution.

Market at a Glance

MetricDetail
Market Size 2024USD 12.4 billion
Market Size 2032USD 18.7 billion
Growth Rate (CAGR)5.3%
Most Critical Decision FactorMedicare Part B reimbursement rate and biosimilar net pricing
Largest RegionSouth Region (U.S. Census Bureau)
Competitive StructureConcentrated branded retina and surgical leaders with fragmented generic tail

Leading Market Participants

  • Alcon
  • Bausch + Lomb
  • Regeneron Pharmaceuticals
  • Genentech
  • Novartis
  • AbbVie
  • Santen Pharmaceutical
  • Ocular Therapeutix
  • Harrow
  • Sun Pharmaceutical Industries

Regulatory and Policy Environment

The Federal Food, Drug, and Cosmetic Act of 1938, as amended, governs ophthalmic drug approval, labelling, and manufacturing, with FDA's Center for Drug Evaluation and Research as primary administrator. PDUFA VII sets user-fee-funded review timelines through 2027. The Anti-Kickback Statute, 42 U.S.C. section 1320a-7b(b), and the Physician Payments Sunshine Act, administered through CMS Open Payments, restrict manufacturer benefits to ophthalmologists who administer injectables, with disclosure required for each payment above USD 10.

Upcoming changes will reshape compliance. PDUFA VIII negotiations must conclude before reauthorization in September 2027. The first Part B selection list for 2028 negotiated prices is due by February 1, 2026, and Part D cycle prices take effect in 2027. Compared with the European Medicines Agency's centralised procedure under Regulation (EC) No 726/2004, the U.S. system carries user-fee timelines alongside price-negotiation exposure absent in most European markets.

Long-Term Policy Outlook for Ophthalmic Medicines in the United States

By 2032 the Part B negotiation regime will operate on intravitreal biologics, following selection for 2028 pricing. The ASP-plus-eight-percent biosimilar add-on expires after 2027, so manufacturers will rely on net price competition rather than reimbursement premiums. FDA's June 2024 draft guidance removing comparative switching studies for biosimilar interchangeability will accelerate pharmacy-level substitution.

PDUFA VIII, covering fiscal years 2028 through 2032, will define review timelines for ophthalmic applications across the forecast window. Medicare Advantage and Part D plans will shift toward biosimilar formulary preference, reshaping retail share in topical and implant categories. Gene therapy reimbursement for inherited retinal disease will require CMS coverage determinations, establishing a durable pricing framework for orphan ophthalmic products.

Frequently Asked Questions

FDA's Center for Drug Evaluation and Research reviews ophthalmic new drug applications under PDUFA VII timelines. Biologics such as anti-VEGF antibodies are reviewed through the same center under the BPCIA pathway.
Medicare Part B reimburses intravitreal drugs at average sales price plus six percent, with qualifying biosimilars receiving eight percent through 2027. Manufacturers must submit quarterly ASP data to CMS to maintain reimbursement eligibility.
The Anti-Kickback Statute and the Physician Payments Sunshine Act require disclosure of any payment above USD 10 through CMS Open Payments. Violations carry civil monetary penalties and possible exclusion from federal health programmes.
Yes, the IRA introduces Medicare price negotiation for selected drugs and a USD 2,000 Part D out-of-pocket cap from 2025. Selected Part B biologics enter the negotiation cycle with negotiated prices effective from 2028.
Yes, when prepared by a registered 503B outsourcing facility under FDA oversight and USP chapter 797 standards. Repackaged syringes from unregistered facilities fall outside that safe harbour.

Market Segmentation

By Therapeutic Area
  • Retina
  • Glaucoma
  • Dry Eye Disease
  • Anterior Segment Surgery
  • Allergic Conjunctivitis
By Drug Type
  • Anti-VEGF Biologics
  • Biosimilars
  • Topical Small Molecules
  • Sustained-Release Implants
  • Gene Therapies
By Distribution Channel
  • Physician Office Administration
  • Retail Pharmacies
  • Hospital Outpatient Pharmacies
  • Mail-Order Specialty Pharmacies
  • Veterans Affairs Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Ophthalmic Drugs - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Therapeutic Area Insights
4.1 Retina
4.2 Glaucoma
4.3 Dry Eye Disease
4.4 Anterior Segment Surgery
4.5 Others
Chapter 05 Drug Type Insights
5.1 Anti-VEGF Biologics
5.2 Biosimilars
5.3 Topical Small Molecules
5.4 Sustained-Release Implants
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Physician Office Administration
6.2 Retail Pharmacies
6.3 Hospital Outpatient Pharmacies
6.4 Mail-Order Specialty Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Alcon
7.2.2 Bausch + Lomb
7.2.3 Regeneron Pharmaceuticals
7.2.4 Genentech
7.2.5 Novartis
7.2.6 AbbVie
7.2.7 Santen Pharmaceutical
7.2.8 Ocular Therapeutix
7.2.9 Harrow
7.2.10 Sun Pharmaceutical Industries
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.